DispersinB(R) Topical Spray Approval from Health Canada's LRVHP Program
07 Janvier 2014 - 2:00PM
Marketwired
DispersinB(R) Topical Spray Approval from Health Canada's LRVHP
Program
WINNIPEG, MANITOBA--(Marketwired - Jan 7, 2014) - Kane Biotech
Inc. (TSX-VENTURE:KNE), a biotechnology company engaged in the
development and commercialization of products that prevent and
remove microbial biofilms, is pleased to announce it has received
Notification Number "NN.XZ5M" from the Interim Notification Program
for Low Risk Veterinary Health Products (LRVHP) for the Company's
first dermatological formulation (under the brand name DispersinB).
DispersinB Topical Spray is a unique antibiofilm-antimicrobial and
non-antibiotic formulation that can be applied to the skin and coat
of dogs and horses.
Atopic dermatitis is a genetically predisposed inflammatory and
pruritic allergic skin disease. It is associated with environmental
allergens including dust mites, pollens, mold spores, dander
insects and microbial infections as well as cutaneous barrier
defects. It is estimated that 10 to 15% of dogs are affected by
atopic dermatitis. Recent research indicates the presence of
staphylococci and Malassezia biofilm in atopic dermatitis
lesions. DispersinB Topical Spray is effective on
Methicillin-Resistant Staphylococcus pseudintermedius
(MRSP) and Malassezia pachydermatis growth and biofilm
formation. In humans, atopic dermatitis is also known as atopic
eczema an inflammatory, relapsing and pruritic or itchy skin
disorder.
"This new DispersinB formulation will be welcome news for the
notorious atopic dermatitis skin disorder that is prevalent in many
pets," stated Gord Froehlich, President and CEO of Kane Biotech.
"The approval also opens the door to additional innovative
DispersinB wound care opportunities as we build on our strong
animal health sector collaborations to move this technology towards
commercialization."
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the
development and commercialization of products to prevent and remove
biofilms. Biofilms are a major cause of a number of serious medical
problems including chronic infections and medical device related
infections. They develop on surfaces such as catheters, prosthetic
implants, teeth, lungs and the urogenital tract. Biofilms are
pervasive, costly to deal with and are involved in approximately
80% of all human bacterial infections. The healing of chronic
wounds alone costs the United States health care system $20 billion
per year.
Kane Biotech uses patent protected technologies based on
molecular mechanisms of biofilm formation/dispersal and methods for
finding compounds that inhibit or disrupt biofilms. The Company has
evidence that these technologies have potential to significantly
improve the ability to prevent and/or destroy biofilms in several
medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release
constitute forward-looking information within the meaning of
applicable Canadian provincial securities legislation
(collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, including, without limitation, our anticipated future
operating results, and can, in some cases, be identified by the use
of words such as "believe," "anticipate," "expect," "intend,"
"plan," "will," "may" and other similar expressions. In addition,
any statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and
are based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
Kane's early stage of development, lack of product revenues and
history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in Kane's filings with Canadian securities
regulatory authorities, as well as Kane's ability to anticipate and
manage the risks associated with the foregoing. Kane cautions that
the foregoing list of important factors that may affect future
results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.
These risks and uncertainties should be considered carefully
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Kane cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update
or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks
of Kane Biotech Inc. All Rights Reserved 2014
Pure Advertising and MarketingKam ThindalPresident604-566-9236
(office) or 604-488-9875 (mobile)kam@puread.caKane Biotech Inc.Gord
FroehlichPresident &
CEO204-477-7592204-474-7552ir@kanebiotech.comwww.kanebiotech.com
Kane Biotech (TSXV:KNE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Kane Biotech (TSXV:KNE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024